Project Grant HT94252410403
Award Date 6/1/24
Completion Date 5/31/26
Dollars Obligated $368K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
- The federal Project Grant award of $591,096.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the St. Vincent's Institute of Medical Research in Australia. The goal of the research is to prevent bone marrow failure in Fanconi anemia through FANCM inhibition. The award has a performance period from July 15, 2025 to July 14, 2028. The St. Vincent's Institute of Medical Research is a foreign-owned, non-profit...
- The U.S. Department of Defense's Defense Health Agency has awarded a $466,234 Project Grant to the University of Queensland in Australia to conduct "PROOF-OF-CONCEPT STUDIES FOR A NOVEL IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER AND COMPANION DIAGNOSTIC." This research grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments and diagnostic tools to improve care for military service members, veterans, and their...
- The U.S. Defense Health Agency awarded a $437,975 Project Grant to the University of New South Wales, doing business as The University of NSW, to conduct research on "TARGETING THE NOVEL LONG NONCODING RNA PRKCQ-AS1 FOR CANCER THERAPY". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for U.S. Service Members and the public. The funded research aims...
- The Department of Defense's Defense Health Agency awarded a $1,205,784 Project Grant to Queensland University of Technology (QUT) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "ACCELERATING TRANSLATION OF A NOVEL METAP2 INHIBITOR IN TREATMENT-RESISTANT AND AGGRESSIVE-VARIANT PROSTATE CANCER," runs from July 1, 2024 to June 30, 2027. The project aims to accelerate the translation of a novel MetAP2 inhibitor therapy for treating...
- The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
- The Defense Health Agency awarded a $4,319,388 Project Grant to the University of Melbourne to fund research aimed at "TARGETING SENESCENT CELLS TO IMPROVE OUTCOMES FOR BREAST CANCER PATIENTS" over the period from September 1, 2024 to August 31, 2028. This grant is provided under the Military Medical Research and Development Program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
- The Defense Health Agency awarded a $159,892 Project Grant to the University of Illinois under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into "Metabolic Vulnerabilities Associated to G12C Inhibitor Resistance" from January 1, 2022 through December 31, 2023. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will...
- The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
- This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
- The Defense Health Agency awarded a $744,997 Project Grant to the University of Queensland in Australia under the Military Medical Research and Development program (CFDA 12.420). This grant, titled "DISCOVERING THERAPEUTIC VULNERABILITIES OF CIRCULATING MELANOMA CLUSTERS," provides funding for the university to conduct cutting-edge biomedical research on melanoma from June 1, 2024 through May 31, 2027. The University of Queensland, a leading research institution in Australia, has an...